GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

Scientists at a university in the UK are in the midst of creating a breakthrough vaccine that could stop cancer in its tracks ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles: London, UK Wednesday, January 29, 2025, 13:00 Hrs ...

Oxford University is hoping to create a vaccine to stop the disease 20 years before it develops, as part of a joint project ...

(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...